Board of Directors

record of building and growing businesses across the Globe. He has a strong track record across the pharmaceutical value chain in both Mature and Emerging Markets.

From July 2021 to January 2023, Abbas was CEO of Vifor Pharmaceuticals– a Swiss listed Nephrology focused Specialty Pharma company which was acquired in 2022 for circa $12Bn in one of the largest health care deals of the year.

Abbas currently holds various Non-Executive Director and Advisor roles including Alfasigma SpA, 4Bio Capital, C-Bridge Capital, Asceneuron SA, and GLG Institute.  He previously held various Non-Executive Director roles including Cochlear Limited, CSL, Teva Pharmaceutical, Immunocore and advisory roles with companies such as Hikma Plc, Cell Research Corp, Abingworth and Indegene Inc.  Abbas provides ad hoc consultancy services to PE and VC.

Prior to his current portfolio of Non-Executive Director roles, Abbas was at GlaxoSmithKline for over ten years.  During his tenure at GlaxoSmithKline, Abbas was a member of the Corporate Executive Team and a Non-Executive Director of ViiV Healthcare. In December 2014, Abbas was appointed President, Global Pharmaceuticals with responsibilities for the Pharmaceuticals operations Europe, US and Emerging Markets & Asia.

Prior to GlaxoSmithKline, Abbas was President, Europe at Eli Lilly and before that Vice President, Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions.  Abbas joined Lilly UK in 1988 and took on roles of increasing responsibility in Sales, Marketing and Business Development before his appointment as Managing Director of Turkey in 1998.  He then became General Manager, Lilly Deutschland.

Abbas is married to Susan and has 3 children.

Naveed joined Novo Holdings A/S in 2019 and is a Senior Partner, Venture Investments.  Novo Holdings manages over USD 30 billion in Investment Assets on behalf of the Novo Nordisk Foundation.

He brings more than 25 years of experience in pre-clinical and clinical stage life science venture investments in Europe and the US.  Between 2013 and 2018, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over 2 billion euros under management, focusing on life science investing.  He has also previously worked in a variety of investment and banking roles at Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance. In the earliest part of his career, he worked and trained financially at KPMG and as a medical doctor in the UK’s National Health Service.

Naveed has served on multiple European and US boards.  At Novo Holdings he has represented the firm on the Boards of Reviral Ltd (acquired by Pfizer), Vectivbio Holding AG (IPO on NASDAQ and acquired by Ironwood), Amolyt SAS (acquired by AstraZeneca), Alentis Therapeutics AG, Asceneuron SA and F2G Ltd. In addition, he is a Board Observer on the board of Numab AG (subsidiary acquisition announced by Johnson & Johnson), member of the Novo Holdings Venture investments’ leadership team, Chair of the Novo Holdings Asia Pte Investment Committee and sits on the LP advisory committee of two early-stage European life science funds.

Philip Scheltens is Partner and Head of the Dementia Fund in the EQT Life Sciences team. Philip was Managing Partner at LSP from 2021 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. previously called LSP (Life Sciences Partners).

Prior to joining LSP, Philip worked as a Director of the Alzheimer Center at Amsterdam University Medical Center in Amsterdam, The Netherlands.

Philip is an MD (neurology) and holds a PhD in Medicine from the VU University Amsterdam and is Professor of Neurology at the Amsterdam University Medical Center.

Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of MedDay from April 2016 to January 2021. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.

Ms. Moukheibir currently serves on the board of directors and chairs the audit committee of Biotalys, Orphazyme A/S, Ironwood Pharmaceuticals and CMR Surgical. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA, Creabilis S.A., GenKyoTex S.A., Kymab Group Ltd and Zealand Pharma A/S. She has an M.A. in economics and an M.B.A. from Yale University. Ms. Moukheibir’s long leadership career in the biopharmaceutical industry, as well as her deep background in international finance, provide her with valuable business and financial expertise in support of our corporate objectives.